CCK-induced pancreatic growth is not limited by mitogenic capacity in mice

Stephen J. Crozier, Maria Dolors Sans, Charles H. Lang, Louis G. D'Alecy, Stephen A. Ernst, John A. Williams

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

In mice fed trypsin inhibitor (camostat) to elevate endogenous CCK, pancreatic growth plateaus by 7 days. It is unknown whether this represents the maximum growth capacity of the pancreas. To test the ability of CCK to drive further growth, mice were fed chow containing camostat (0.1%) for 1 wk, then fed standard chow for 1 wk, and finally returned to the camostat diet for a week. Pancreatic mass increased to 245% of initial value (iv) following 1 wk of camostat feeding, decreased to 147% iv following a 1 wk return to normal chow, and increased to 257% iv with subsequent camostat feeding. Camostat feeding was associated with significant increases in circulating CCK and changes in pancreatic mass were paralleled by changes in protein and DNA content. Moreover, regression of the pancreas following camostat feeding was associated with changes in the expression of the autophagosome marker LC3. Pancreatic protein synthetic rates were 130% of control after 2 days on camostat but were equivalent to control after 7 days. Changes in the phosphorylation of 4E-BP1 and S6, downstream effectors of mammalian target of rapamycin (mTOR), paralleled changes in protein synthetic rates. Cellular content of Akt, an upstream activating kinase of mTOR, decreased after 7 days of camostat feeding whereas expression of the E3 ubiquitin-ligases and the cell cycle inhibitor p21 increased after 2 days. These results indicate that CCK-stimulated growth of the pancreas is not limited by acinar cell mitogenic capacity but is due, at least in part, to inhibition of promitogenic Akt signaling.

Original languageEnglish (US)
JournalAmerican Journal of Physiology - Gastrointestinal and Liver Physiology
Volume294
Issue number5
DOIs
StatePublished - May 1 2008

Fingerprint

Growth
Pancreas
Sirolimus
camostat
S 6
Proteins
Ubiquitin-Protein Ligases
Trypsin Inhibitors
Acinar Cells
Cell Cycle
Phosphotransferases
Phosphorylation
Diet
DNA

All Science Journal Classification (ASJC) codes

  • Physiology
  • Hepatology
  • Gastroenterology
  • Physiology (medical)

Cite this

@article{c2d1e1ad2d3a4d87ad34c5bc45d9a2af,
title = "CCK-induced pancreatic growth is not limited by mitogenic capacity in mice",
abstract = "In mice fed trypsin inhibitor (camostat) to elevate endogenous CCK, pancreatic growth plateaus by 7 days. It is unknown whether this represents the maximum growth capacity of the pancreas. To test the ability of CCK to drive further growth, mice were fed chow containing camostat (0.1{\%}) for 1 wk, then fed standard chow for 1 wk, and finally returned to the camostat diet for a week. Pancreatic mass increased to 245{\%} of initial value (iv) following 1 wk of camostat feeding, decreased to 147{\%} iv following a 1 wk return to normal chow, and increased to 257{\%} iv with subsequent camostat feeding. Camostat feeding was associated with significant increases in circulating CCK and changes in pancreatic mass were paralleled by changes in protein and DNA content. Moreover, regression of the pancreas following camostat feeding was associated with changes in the expression of the autophagosome marker LC3. Pancreatic protein synthetic rates were 130{\%} of control after 2 days on camostat but were equivalent to control after 7 days. Changes in the phosphorylation of 4E-BP1 and S6, downstream effectors of mammalian target of rapamycin (mTOR), paralleled changes in protein synthetic rates. Cellular content of Akt, an upstream activating kinase of mTOR, decreased after 7 days of camostat feeding whereas expression of the E3 ubiquitin-ligases and the cell cycle inhibitor p21 increased after 2 days. These results indicate that CCK-stimulated growth of the pancreas is not limited by acinar cell mitogenic capacity but is due, at least in part, to inhibition of promitogenic Akt signaling.",
author = "Crozier, {Stephen J.} and Sans, {Maria Dolors} and Lang, {Charles H.} and D'Alecy, {Louis G.} and Ernst, {Stephen A.} and Williams, {John A.}",
year = "2008",
month = "5",
day = "1",
doi = "10.1152/ajpgi.00426.2007",
language = "English (US)",
volume = "294",
journal = "American Journal of Physiology",
issn = "0193-1849",
publisher = "American Physiological Society",
number = "5",

}

CCK-induced pancreatic growth is not limited by mitogenic capacity in mice. / Crozier, Stephen J.; Sans, Maria Dolors; Lang, Charles H.; D'Alecy, Louis G.; Ernst, Stephen A.; Williams, John A.

In: American Journal of Physiology - Gastrointestinal and Liver Physiology, Vol. 294, No. 5, 01.05.2008.

Research output: Contribution to journalArticle

TY - JOUR

T1 - CCK-induced pancreatic growth is not limited by mitogenic capacity in mice

AU - Crozier, Stephen J.

AU - Sans, Maria Dolors

AU - Lang, Charles H.

AU - D'Alecy, Louis G.

AU - Ernst, Stephen A.

AU - Williams, John A.

PY - 2008/5/1

Y1 - 2008/5/1

N2 - In mice fed trypsin inhibitor (camostat) to elevate endogenous CCK, pancreatic growth plateaus by 7 days. It is unknown whether this represents the maximum growth capacity of the pancreas. To test the ability of CCK to drive further growth, mice were fed chow containing camostat (0.1%) for 1 wk, then fed standard chow for 1 wk, and finally returned to the camostat diet for a week. Pancreatic mass increased to 245% of initial value (iv) following 1 wk of camostat feeding, decreased to 147% iv following a 1 wk return to normal chow, and increased to 257% iv with subsequent camostat feeding. Camostat feeding was associated with significant increases in circulating CCK and changes in pancreatic mass were paralleled by changes in protein and DNA content. Moreover, regression of the pancreas following camostat feeding was associated with changes in the expression of the autophagosome marker LC3. Pancreatic protein synthetic rates were 130% of control after 2 days on camostat but were equivalent to control after 7 days. Changes in the phosphorylation of 4E-BP1 and S6, downstream effectors of mammalian target of rapamycin (mTOR), paralleled changes in protein synthetic rates. Cellular content of Akt, an upstream activating kinase of mTOR, decreased after 7 days of camostat feeding whereas expression of the E3 ubiquitin-ligases and the cell cycle inhibitor p21 increased after 2 days. These results indicate that CCK-stimulated growth of the pancreas is not limited by acinar cell mitogenic capacity but is due, at least in part, to inhibition of promitogenic Akt signaling.

AB - In mice fed trypsin inhibitor (camostat) to elevate endogenous CCK, pancreatic growth plateaus by 7 days. It is unknown whether this represents the maximum growth capacity of the pancreas. To test the ability of CCK to drive further growth, mice were fed chow containing camostat (0.1%) for 1 wk, then fed standard chow for 1 wk, and finally returned to the camostat diet for a week. Pancreatic mass increased to 245% of initial value (iv) following 1 wk of camostat feeding, decreased to 147% iv following a 1 wk return to normal chow, and increased to 257% iv with subsequent camostat feeding. Camostat feeding was associated with significant increases in circulating CCK and changes in pancreatic mass were paralleled by changes in protein and DNA content. Moreover, regression of the pancreas following camostat feeding was associated with changes in the expression of the autophagosome marker LC3. Pancreatic protein synthetic rates were 130% of control after 2 days on camostat but were equivalent to control after 7 days. Changes in the phosphorylation of 4E-BP1 and S6, downstream effectors of mammalian target of rapamycin (mTOR), paralleled changes in protein synthetic rates. Cellular content of Akt, an upstream activating kinase of mTOR, decreased after 7 days of camostat feeding whereas expression of the E3 ubiquitin-ligases and the cell cycle inhibitor p21 increased after 2 days. These results indicate that CCK-stimulated growth of the pancreas is not limited by acinar cell mitogenic capacity but is due, at least in part, to inhibition of promitogenic Akt signaling.

UR - http://www.scopus.com/inward/record.url?scp=45849141220&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45849141220&partnerID=8YFLogxK

U2 - 10.1152/ajpgi.00426.2007

DO - 10.1152/ajpgi.00426.2007

M3 - Article

VL - 294

JO - American Journal of Physiology

JF - American Journal of Physiology

SN - 0193-1849

IS - 5

ER -